Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?

Current Gene Therapy

Volumn 9, Issue 5, 2009, Pages 368-374

  Lowenstein, Pedro R ^a   Castro, Maria G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bayesian statistics; Cancer; Effect size; Gene therapy; Glioblastoma multiforme; Phase III clinical trials

Indexed keywords

TEMOZOLOMIDE;

BAYES THEOREM; BIOLOGICAL MODEL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DRUG TREATMENT FAILURE; EFFECT SIZE; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; GENE THERAPY; GLIOBLASTOMA; HEALTH CARE PLANNING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATIENT CARE; PREDICTION; QUALITY CONTROL; REPRODUCIBILITY; RESEARCH PRIORITY; REVIEW; STATISTICAL MODEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CLINICAL TRIALS, PHASE III AS TOPIC; GENE THERAPY; UNCERTAINTY;

EID: 73449115350     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309789753392     Document Type: Review

References (52)

1. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-221.
2. Amarasingh S, Macleod MR, Whittle IR. What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma. J Neurooncol 2009; 91: 117-25.
3. Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 2001: CD002034.
4. Hart MG, Grant R, Garside R, et al. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2008: CD007415.
5. Perel P, Roberts I, Sena E, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. Bmj 2007; 334: 197.
6. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9: 833-42.
7. nd ed. Wiley-Interscience: London, New York 2005.
8. Goodman SN. Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med 1999; 130: 995-1004.
9. Goodman SN. Toward evidence-based medical statistics. 2: the Bayes factor. Ann Intern Med 1999; 130: 1005-13.
10. Miksad RA, Gonen M, Lynch TJ, Roberts TG, Jr. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol 2009; 27: 2245-52.
11. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25: 4506-7; author reply 8.
12. Ioannidis JP. Why most published research findings are false. PLoS Med 2005; 2: e124.
13. Goodman S, Greenland S. Why most published research findings are false: problems in the analysis. PLoS Med 2007; 4: e168.
14. Goodman S, Greenland S. Assessing the unreliability of the medical literature: a response to "Why most published research findings are false". Johns Hopkins University, Department of Biostatistics.; 2007; Available from: http://www.bepress.com/ jhubiostat/ paper135.
15. Buckner JC, Ed. Central nervous system tumors (Discussion) - Central nervous system tumors track. ASCO Annual Meeting, 2009.
16. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
17. Grossman SA, Ye X, Piantadosi S, et al., editors. Current survival statistics for patients with newly diagnosed glioblastoma treated with radiation and temozolomide on research studies in the United States. ASCO Annual Meeting 2009.
18. Markman JR, Markman M. Running an ethical trial 60 years after the Nuremberg Code. Lancet Oncol 2007; 8: 1139-46.
19. Weindling P. The origins of informed consent: the International Scientific Commission on Medical War Crimes, and the Nuremburg code. Bull Hist Med 2001; 75: 37-71.
20. Ernst E, Weindling PJ. The nuremberg medical trial: have we learned the lessons? J Lab Clin Med 1998; 131: 130-5.
21. Candolfi M, Curtin JF, Nichols WS, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007; 85: 133-48.
22. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol 2009; 92: 23-31.
23. Ashley DM, Kong FM, Bigner DD, Hale LP. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model. Cancer Res 1998; 58: 302-9.
24. Marumoto T, Tashiro A, Friedmann-Morvinski D, et al. Development of a novel mouse glioma model using lentiviral vectors. Nat Med 2009; 15: 110-6.
25. Shih AH, Dai C, Hu X, et al. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 2004; 64: 4783-9.
26. Assanah M, Lochhead R, Ogden A, et al. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 2006; 26: 6781-90.
27. Wiesner SM, Decker SA, Larson JD, et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res 2009; 69: 431-9.
28. Huse JT, Holland EC. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 2009; 19: 132-43.
29. Ghulam Muhammad AK, Candolfi M, King GD, et al. Anti-glioma immunological memory in response to conditional cytotoxic/ immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 2009; 15(19): 6113-27.
30. Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 2009; 15: 4401-14.
31. Curtin J, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 2009; 6: e10.
32. Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 2005; 65: 7194-204.
33. Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999; 5: 1256-63.
34. McCloskey DN, Ziliak S. The cult of statistical significance: how the standard error costs us jobs, justice, and lives (Economics, Cognition, and Society): University of Michigan Press: Ann Arbor, MI 2008.
35. Curran-Everett D. Explorations in statistics: hypothesis tests and P values. Adv Physiol Educ 2009; 33: 81-6.
36. Curran-Everett D. Explorations in statistics: confidence intervals. Adv Physiol Educ 2009; 33: 87-90.
37. Fisher RA. Statistical methods for research workers. London: Oliver and Boyd 1925.
38. Fisher RA. The arrangement of field experiments. J Minist Agric 1926; GB 33: 503-13.
39. Bearer EL, Lowengrub JS, Frieboes HB, et al. Multiparameter computational modeling of tumor invasion. Cancer Res 2009; 69: 4493-501.
40. Macklin P, McDougall S, Anderson AR, et al. Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol 2009; 58: 765-98.
41. Harpold HL, Alvord EC, Jr., Swanson KR. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol 2007; 66: 1-9.
42. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009; 69: 4502-9.
43. Carlson JM, Doyle J. Complexity and robustness. Proc Natl Acad Sci USA 2002; 99 (Suppl 1): 2538-45.
44. Sandercock P, Roberts I. Systematic reviews of animal experiments. Lancet 2002; 360: 586.
45. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc 2007; 82: 591-605.
46. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006; 59: 990-6.
47. Diamond GA, Kaul S. Bayesian classification of clinical practice guidelines. Arch Intern Med 2009; 169: 1431-5.
48. Goodman SN. Building a Bayesian bridge from evidence to guidelines. Arch Intern Med 2009; 169: 1436-7.
49. Lowenstein PR. A call for physiopathological ethics. Mol Ther 2008; 16: 1771-2.
50. Lowenstein PR. Clinical trials in gene therapy: ethics of informed consent and the future of experimental medicine. Curr Opin Mol Ther 2008; 10: 428-30.
51. Kimmelman J. The ethics of human gene transfer. Nat Rev Genet 2008; 9: 239-44.
52. Kimmelman J. Ethics of cancer gene transfer clinical research. Methods Mol Biol 2009; 542: 423-45.